arrow_back Civic Audit
Share share

Study of Drug Pricing and Intermediaries in the Pharmaceutical Supply Chain

This act requires the Federal Trade Commission to study how intermediaries affect drug prices and competition. The goal is to understand if current practices lead to higher costs for patients and if there are legal obstacles to enforcing regulations. Citizens can expect that the results of this study will help lower drug prices and increase market transparency in the future.
Key points
The Federal Trade Commission will investigate whether pharmacy benefit managers (PBMs) charge payers higher prices than they reimburse pharmacies.
It will be examined whether PBMs steer patients to pharmacies in which they have an ownership interest, and whether they use pharmacy data to increase their profits.
The Commission will analyze if current regulations hinder the fight against unfair practices in the drug market and propose changes that could lower drug prices for consumers.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Placed on Calendar
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Print number: 119_S_527
Sponsor: Sen. Grassley, Chuck [R-IA]
Process start date: 2025-02-11
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Prescription Pricing for the People Act of 2025

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_S_527.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2025-02-11.

What are the main provisions?

Key points include:

  • The Federal Trade Commission will investigate whether pharmacy benefit managers (PBMs) charge payers higher prices than they reimburse pharmacies.
  • It will be examined whether PBMs steer patients to pharmacies in which they have an ownership interest, and whether they use pharmacy data to increase their profits.
  • The Commission will analyze if current regulations hinder the fight against unfair practices in the drug market and propose changes that could lower drug prices for consumers.
What is the specific legal status?

The current status is Placed on Calendar.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Grassley, Chuck [R-IA].

What is the latest detailed status?

The latest detailed status is: Placed on Senate Legislative Calendar under General Orders. Calendar No. 42.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

What is the impact of this bill?

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge.

CATEGORIES

Health Economy Courts and Law